Home/ Stocks/ ACHV

Achieve Life Sciences, Inc.

ACHV XNAS

$6.72 +0.28 (+4.31%) ▲ 15-min delayed

Open

$6.55

High

$6.75

Low

$6.25

Volume

1.08M

Market Cap

$692.85M

About Achieve Life Sciences, Inc.

Achieve Life Sciences Inc is a late-stage specialty pharmaceutical company focused on the world-wide development and commercialization of cytisinicline as a treatment for nicotine dependence. Its New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two completed Phase 3 studies and an open-label long-term safety study. It has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.

Sector: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES Employees: 28 Website →

Related Market News

No specific coverage for ACHV yet. Check out our latest market news or earnings calendar.

Get ACHV Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Achieve Life Sciences, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.